Soleno Therapeutics Q1 2024 Adj EPS $(0.59) Misses $(0.37) Estimate
Portfolio Pulse from Benzinga Newsdesk
Soleno Therapeutics reported a Q1 2024 adjusted EPS loss of $(0.59), missing the consensus estimate of $(0.37) by 59.46%.
May 09, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Soleno Therapeutics reported a larger than expected Q1 2024 loss per share of $(0.59), missing the $(0.37) estimate significantly.
Missing earnings estimates by a significant margin often leads to negative investor sentiment and can result in a short-term decline in stock price. The substantial miss in EPS for Soleno Therapeutics is likely to negatively impact investor confidence and could lead to a decrease in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100